Farxiga vs Tresiba: Switching Between Dapagliflozin and Insulin Degludec

Two Completely Different Drug Classes

Farxiga and Tresiba work through mechanisms that share no overlap. The clinical decision to use one, the other, or both depends on where a patient stands in the progression of type 2 diabetes and what comorbidities are present.

Farxiga (dapagliflozin) belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class. It blocks glucose reabsorption in the proximal tubule of the kidney, causing the body to excrete roughly 60 to 80 grams of glucose daily through urine 1. This insulin-independent mechanism means Farxiga works regardless of how much insulin the pancreas still produces. The FDA approved dapagliflozin for type 2 diabetes in 2014, for heart failure with reduced ejection fraction in 2020, and for chronic kidney disease in 2021.

Tresiba (insulin degludec) is a second-generation basal insulin analog with an ultra-long duration of action. After subcutaneous injection, degludec forms multi-hexamer chains in the subcutaneous depot that slowly dissociate, producing a half-life exceeding 25 hours and a duration of action beyond 42 hours 2. That pharmacokinetic profile creates a flatter, more stable glucose-lowering curve than older basal insulins like glargine U100.

The practical difference is straightforward. Farxiga removes glucose through the kidneys without requiring insulin. Tresiba supplies exogenous insulin to suppress hepatic glucose output and lower fasting blood sugar. A patient with significant insulin deficiency needs Tresiba. A patient with adequate endogenous insulin production and cardiorenal risk factors may benefit more from Farxiga.

Cardiovascular and Safety Evidence: DAPA-HF and DEVOTE

Both drugs have been tested in large cardiovascular outcomes trials, though neither trial compared them head-to-head. The evidence base for each drug addresses different clinical questions.

The DAPA-HF trial (N=4,744) randomized patients with heart failure and reduced ejection fraction (EF ≤40%) to dapagliflozin 10 mg or placebo, regardless of diabetes status. At a median follow-up of 18.2 months, dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001) 1. The benefit was consistent across patients with and without type 2 diabetes. The Kansas City Cardiomyopathy Questionnaire scores also improved, reflecting better symptom burden and quality of life.

The DEVOTE trial (N=7,637) was a double-blind cardiovascular outcomes trial comparing insulin degludec to insulin glargine U100 in patients with type 2 diabetes at high cardiovascular risk. Degludec was non-inferior to glargine for three-point MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) with a hazard ratio of 0.91 (95% CI 0.78 to 1.06) 2. The pre-specified secondary endpoint of severe hypoglycemia favored degludec, which showed a 40% lower rate of nocturnal severe hypoglycemia compared to glargine (rate ratio 0.60, P=0.004).

These trials answer different questions. DAPA-HF demonstrated that dapagliflozin actively reduces cardiovascular events. DEVOTE demonstrated that degludec does not increase cardiovascular events and is safer than glargine regarding hypoglycemia. A clinician weighing the two drugs for a patient with heart failure will find stronger evidence supporting Farxiga's cardiorenal benefits, while a clinician managing a patient who needs basal insulin with minimal hypoglycemia risk will favor Tresiba.

A1C Lowering: How They Compare on Glycemic Control

Farxiga produces moderate A1C reductions. Tresiba produces larger reductions that scale with dose titration, but carries the inherent risks of exogenous insulin therapy.

In key trials, dapagliflozin 10 mg reduced A1C by 0.5% to 0.8% as monotherapy and by similar margins when added to metformin, sulfonylureas, or insulin 3. The glycemic effect is self-limiting because once blood glucose drops below the renal threshold (approximately 180 mg/dL), SGLT2 inhibition stops driving additional glucose excretion. This ceiling effect also explains why Farxiga rarely causes hypoglycemia on its own.

Insulin degludec, by contrast, has no ceiling. Dose titration in the BEGIN trial program showed A1C reductions of 1.0% to 1.5% from baselines around 8.0% to 8.5%, with final A1C values routinely reaching 7.0% or below 4. The trade-off is dose-dependent weight gain (typically 1 to 3 kg over 52 weeks) and the need for blood glucose monitoring to guide titration.

For a patient at an A1C of 7.8% who also has heart failure or CKD, Farxiga alone may bring them to target while delivering organ protection. For a patient at an A1C of 10.2% with symptoms of hyperglycemia, Farxiga alone is unlikely to reach goal. That patient needs insulin, and Tresiba's flat pharmacokinetic profile makes it a strong basal choice.

Weight and Metabolic Effects Beyond Glucose

Weight trajectory differs sharply between these two medications, and this difference often influences prescribing decisions and patient preferences.

Dapagliflozin causes caloric loss through glycosuria. Each day, 60 to 80 grams of glucose exits through the urine, representing 240 to 320 lost calories. In clinical practice, this translates to a sustained 2 to 3 kg weight reduction over the first 6 to 12 months 3. The weight loss is modest compared to GLP-1 receptor agonists, but it moves in the right direction for most patients with type 2 diabetes. Farxiga also lowers systolic blood pressure by 3 to 5 mmHg through mild osmotic diuresis and natriuresis 5.

Tresiba, like all exogenous insulin, promotes anabolism. Patients typically gain 1 to 3 kg over the first year of therapy, though this is less than what is seen with some older insulin formulations 4. For patients already struggling with obesity, the prospect of additional weight gain can reduce treatment adherence.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has noted: "The sequencing of diabetes therapies should account for the full metabolic picture, including weight, blood pressure, and cardiorenal risk, not just A1C alone" 6. The 2022 ADA Standards of Care reflect this thinking, placing SGLT2 inhibitors and GLP-1 receptor agonists ahead of insulin for most patients with type 2 diabetes who have established cardiovascular or renal disease 6.

Renal Considerations: Farxiga's CKD Advantage

Kidney function plays a direct role in determining whether Farxiga or Tresiba is appropriate, and at what stage of CKD each drug remains effective.

The DAPA-CKD trial (N=4,304) demonstrated that dapagliflozin 10 mg reduced the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) in patients with CKD, with or without diabetes 5. This led to the FDA's 2021 approval of Farxiga for CKD with an eGFR of 25 to 75 mL/min/1.73 m². The glycemic benefit of Farxiga diminishes as eGFR falls below 45 mL/min, but the cardiorenal protective effects persist even at lower filtration rates.

Tresiba has no renal contraindication. Insulin is metabolized by the kidneys, and as renal function declines, insulin clearance slows. Patients with advanced CKD on Tresiba often require dose reductions to avoid hypoglycemia 2. Blood glucose monitoring becomes more important in this population.

For a patient with type 2 diabetes and an eGFR of 35, Farxiga still confers kidney and heart protection even though its glucose-lowering effect is attenuated. If that patient also needs stronger glycemic control, adding Tresiba at a conservative starting dose is a reasonable and common approach.

When Switching From Tresiba to Farxiga Makes Sense

Stepping down from basal insulin to an SGLT2 inhibitor is possible under specific clinical circumstances. It is not always safe or appropriate, and the transition requires monitoring.

The clinical scenario where this switch works best involves a patient with type 2 diabetes who was started on basal insulin during a period of glucotoxicity or perioperative management, whose A1C has since improved to below 8.0%, and whose fasting glucose is consistently below 150 mg/dL on a low dose of Tresiba (typically <0.3 units/kg/day). If that patient also has heart failure, CKD, or a strong preference to stop injections, transitioning to Farxiga (with continuation of metformin or another oral agent) may be successful.

The process involves adding Farxiga 10 mg daily while simultaneously reducing Tresiba by 20% to 30%. Over the following 2 to 4 weeks, the clinician monitors fasting glucose and adjusts or discontinues Tresiba based on readings. The ADA Standards of Care support insulin de-escalation when A1C and clinical status allow, particularly when patients can be transitioned to agents with cardiorenal benefits 6.

This switch is not appropriate for patients with suspected latent autoimmune diabetes of adults (LADA), those with A1C above 9%, those on high-dose basal insulin (>0.5 units/kg/day, suggesting significant insulin deficiency), or those with an eGFR below 25.

When Switching From Farxiga to Tresiba Makes Sense

Moving from an SGLT2 inhibitor to basal insulin typically signals disease progression. The beta cells are no longer producing enough insulin to maintain glycemic control with oral and non-insulin injectable agents alone.

The typical trigger is a rising A1C despite adherence to Farxiga plus one or two other oral agents (commonly metformin and a sulfonylurea or DPP-4 inhibitor). When A1C exceeds 9.0% to 9.5% and fasting glucose is consistently above 200 mg/dL, adding basal insulin becomes necessary. The 2022 ADA/EASD consensus report recommends initiating basal insulin at 10 units daily (or 0.1 to 0.2 units/kg/day) and titrating by 2 to 4 units every 3 to 7 days to a fasting glucose target of 80 to 130 mg/dL 6.

An important clinical point: do not stop Farxiga when adding Tresiba. The two drugs work through complementary mechanisms, and the SGLT2 inhibitor continues to provide cardiorenal protection, modest glucose lowering, and weight offset against insulin-associated weight gain. The DEPICT trials demonstrated that dapagliflozin added to insulin reduced A1C by an additional 0.3% to 0.4% while decreasing total daily insulin dose by 8% to 13% 7. Keeping both drugs on board is standard practice.

Using Farxiga and Tresiba Together

Combination therapy with an SGLT2 inhibitor and basal insulin is a well-supported treatment strategy. The two drugs complement each other in ways that address the limitations of either agent alone.

Tresiba addresses fasting hyperglycemia through suppression of overnight hepatic glucose output. Farxiga reduces glucose load throughout the day through renal excretion. Together, they cover both fasting and post-absorptive glucose spikes. Real-world data from the Optum claims database (2015 to 2020) showed that patients on SGLT2 inhibitors plus basal insulin achieved a mean A1C of 7.8%, compared to 8.3% for basal insulin alone, with fewer hypoglycemic events 8.

The combination also mitigates weight gain. In the DEPICT-1 trial, patients on insulin who added dapagliflozin lost 0.9 kg at 24 weeks, while those on insulin plus placebo gained 0.4 kg 7. This 1.3 kg difference matters to patients who are already dissatisfied with insulin-related weight increases.

The ADA Standards of Care (2024) explicitly recommend adding an SGLT2 inhibitor to insulin regimens for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD, irrespective of A1C 6.

Cost and Access Differences

The out-of-pocket expense for each drug varies widely by insurance plan, but the list prices and generic availability create meaningful differences in access.

Farxiga's wholesale acquisition cost is approximately $550 to $600 per month for the 10 mg tablet. No generic dapagliflozin is available in the United States as of early 2026. AstraZeneca offers a savings card that can reduce the copay to as low as $0 for commercially insured patients 9.

Tresiba's wholesale acquisition cost ranges from $400 to $550 per month depending on the pen configuration (U100 or U200). Generic insulin degludec is not available in the U.S. Novo Nordisk offers patient assistance programs that can lower costs significantly for eligible individuals.

For patients without insurance, both drugs represent a substantial monthly expense. The choice between them should be driven by clinical need rather than cost alone, but access barriers are real. Clinicians should be aware that some formularies preferentially cover one SGLT2 inhibitor (such as empagliflozin/Jardiance) over another, and similar formulary tiering applies to basal insulins.

Side Effect Profiles

Each drug carries distinct adverse effects that can influence which medication a given patient tolerates better.

Farxiga's most common side effects relate to its mechanism. Glycosuria creates an environment conducive to genital mycotic infections, affecting roughly 6% to 8% of women and 3% to 4% of men in clinical trials 3. Urinary tract infections occur at a slightly higher rate than placebo. Rare but serious risks include euglycemic diabetic ketoacidosis (DKA), which occurs in fewer than 1 in 1,000 patients but requires awareness, particularly in perioperative settings or during acute illness. The FDA issued a DKA warning for all SGLT2 inhibitors in 2015 9. Volume depletion can also occur, especially in elderly patients or those on loop diuretics.

Tresiba's primary risk is hypoglycemia, though DEVOTE showed this risk is lower than with glargine U100. Injection site reactions are uncommon but possible. Weight gain, as discussed above, is a consistent effect. Severe hypoglycemia remains the most dangerous insulin-associated adverse event, occurring at a rate of 2.6 events per 100 patient-years in DEVOTE for degludec versus 3.6 for glargine 2.

Patients with a history of recurrent yeast infections may tolerate Tresiba better. Patients with a history of severe hypoglycemia on other insulins may benefit from Tresiba's flatter profile if insulin is required, or from Farxiga if insulin can be avoided.

Dosing and Practical Administration

Farxiga is taken as a single 10 mg tablet by mouth once daily, preferably in the morning. No titration is needed. The dose does not change based on blood glucose readings. Patients with an eGFR below 25 mL/min/1.73 m² should not initiate Farxiga, though those already on it can continue until dialysis 5.

Tresiba is injected subcutaneously once daily at any time, with a flexible dosing window that allows up to 8 hours of variation between injections without compromising efficacy 4. Starting dose for insulin-naive patients is typically 10 units daily. Titration follows a treat-to-target approach, adjusting by 2 to 4 units every 3 days based on fasting glucose. The flexible timing is a practical advantage over glargine, which requires more consistent injection timing.

According to the Endocrine Society's 2019 clinical practice guideline on the treatment of diabetes in older adults: "Simplified regimens that minimize hypoglycemia risk and reduce injection burden are preferred in patients over age 65" 10. Both Farxiga (oral, no monitoring required) and Tresiba (once-daily, flexible timing, low hypoglycemia) align with this recommendation, making either a reasonable option depending on glucose-lowering needs.